Credit: PrincetonIn April, a
federal court ordered the Obama administration to make Plan B
emergency contraception available without a prescriptionn to all
females of reproductive age. Yesterday, the FDA ruled that women
over the age 15 could have over-the-counter access to the pill.
Also, yesterday the FDA filed an appeal of the district court's
ruling. According to the
Washington Post, the U.S. Justice
Department had the
bald-faced temerity to argue:
“The Court’s Order interferes with and thereby undermines the
regulatory procedures governing FDA’s drug approval process,” the
Justice Department said. “A drug approval decision involves
scientific judgments as to whether statutory and regulatory factors
are met that warrant deference to those charged with the statutory
responsibility to make those decisions.”
So just what exactly was the FDA's
actual scientific
judgment about Plan B. Jumping into our policy
WABAC Machine and
we find the following December 7, 2011
statement
from FDA Administrator Margaret Hamburg:
The Center for Drug Evaluation and Research (CDER) completed its
review of the Plan B One-Step application and laid out its
scientific determination. CDER carefully considered whether younger
females were able to understand how to use Plan B One-Step.
Based on the information submitted to the agency, CDER
determined that the product was safe and effective in adolescent
females, that adolescent females understood the product was not for
routine use, and that the product would not protect them against
sexually transmitted diseases. Additionally, the data supported a
finding that adolescent females could use Plan B One-Step properly
without the intervention of a healthcare provider.
It is our responsibility at FDA to approve drugs that are safe
and effective for their intended use based on the scientific
evidence. The review process used by CDER to analyze the data
applied a risk/benefit assessment consistent with its standard drug
review process. Our decision-making reflects a body of
scientific findings, input from external scientific advisory
committees, and data contained in the application that included
studies designed specifically to address the regulatory standards
for nonprescription drugs. CDER experts, including
obstetrician/gynecologists and pediatricians, reviewed the totality
of the data and agreed that it met the regulatory standard for a
nonprescription drug and that Plan B One-Step should be approved
for all females of child-bearing potential.
I reviewed and thoughtfully considered the data, clinical
information, and analysis provided by CDER, and I agree with the
Center that there is adequate and reasonable, well-supported, and
science-based evidence that Plan B One-Step is safe and effective
and should be approved for nonprescription use for all females of
child-bearing potential.
What's especially ridiculous is that the folks in the Obama
administration overruled the scientific determinations of the FDA
and arbitrarily imposed age restrictions on the availability of
Plan B out obvious electoral considerations. Since the president
can't run for office again, the only plausible reason that the
Justice Department would oppose making Plan B available without a
prescription to all women of reproductive age now is out of sheer
embarassment at the fact the administration would be admitting its
original decision was completely political.
No comments:
Post a Comment